Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4- fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248)

Journal of Medicinal Chemistry

Volumn 56, Issue 4, 2013, Pages 1656-1669

  Regueiro Ren, Alicia ^a   Xue, Qiufen M ^a   Swidorski, Jacob J ^a   Gong, Yi Fei ^a   Mathew, Marina ^a   Parker, Dawn D ^a   Yang, Zheng ^a   Eggers, Betsy ^a   D'Arienzo, Celia ^a   Sun, Yongnian ^a   Malinowski, Jacek ^a   Gao, Qi ^a   Wu, Dedong ^a   Langley, David R ^a   Colonno, Richard J ^a   Chien, Caly ^a   Grasela, Dennis M ^a   Zheng, Ming ^a   Lin, Pin Fang ^a   Meanwell, Nicholas A ^a   Kadow, John F ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 BENZOYLPIPERAZIN 1 YL) 2 (4 FLUORO 7 (OXAZOL 5 YL) 1H PYRROLO[2,3 C]PYRIDIN 3 YL)ETHANE 1,2 DIONE; 1 (4 BENZOYLPIPERAZIN 1 YL) 2 (7 BROMO 4 FLUORO 1H PYRROLO[2,3 C]PYRIDIN 3 YL)ETHANE 1,2 DIONE; 1 (4 BENZOYLPIPERAZIN 1 YL) 2 [4 FLUORO 7 (1H 1,2,4 TRIAZOL 1 YL) 1H PYRROLO[2,3 C]PYRIDIN 3 YL]ETHANE 1,2 DIONE; 1 (4 BENZOYLPIPERAZIN 1 YL) 2 [4 FLUORO 7 (1H IMIDAZOL 1 YL) 1H PYRROLO[2,3 C]PYRIDIN 3 YL]ETHANE 1,2 DIONE; 1 (4 BENZOYLPIPERAZIN 1 YL) 2 [4 FLUORO 7 (1H PYRAZOL 1 YL) 1H PYRROLO[2,3 C]PYRIDIN 3 YL]ETHANE 1,2 DIONE; 1 (4 BENZOYLPIPERAZIN 1 YL) 2 [4 FLUORO 7 (1H PYRAZOL 3 YL) 1H PYRROLO[2,3 C]PYRIDIN 3 YL]ETHANE 1,2 DIONE; 1 (4 BENZOYLPIPERAZIN 1 YL) 2 [4 FLUORO 7 (PYRAZIN 2 YL) 1H PYRROLO[2,3 C]PYRIDIN 3 YL]ETHANE 1,2 DIONE; 1 (4 BENZOYLPIPERAZIN 1 YL) 2 [4 FLUORO 7 (PYRIMIDIN 5 YL) 1H PYRROLO[2,3 C]PYRIDIN 3 YL]ETHANE 1,2 DIONE; 2 (7 BROMO 4 FLUORO 1H PYRROLO[2,3 C]PYRIDIN 3 YL) 2 OXOACETIC ACID; 3 [2 (4 BENZOYLPIPERAZIN 1Y L) 2 OXOACETYL] 4 FLUORO 1H PYRROLO[2,3 C]PYRIDINE 7 CARBOXAMIDE; 3 [3 [2 (4 BENZOYLPIPERAZIN 1 YL) 2 OXOACETYL] 4 FLUORO 1H PYRROLO[2,3 C]PYRIDIN 7 YL) N (2 MORPHOLINOETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 3 [3 [2 (4 BENZOYLPIPERAZIN 1 YL) 2 OXOACETYL] 4 FLUORO 1H PYRROLO[2,3 C]PYRIDIN 7 YL) N METHYL 1H PYRAZOLE 5 CARBOXAMIDE; 3 [3 [2 (4 BENZOYLPIPERAZIN 1 YL) 2 OXOACETYL] 4 FLUORO 1H PYRROLO[2,3 C]PYRIDIN 7 YL) N,N DIMETHYL1 H PYRAZOLE 5 CARBOXAMIDE; 7 BROMO 4 FLUORO 1H PYRROLO[2,3 C]PYRIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BMS 585248; EFAVIRENZ; ETHYL 3 [3 [2 (4 BENZOYLPIPERAZIN 1 YL) 2 OXOACETYL] 4 FLUORO 1H PYRROLO[2,3 C]PYRIDIN 7 YL) 1H PYRAZOLE 5 CARBOXYLATE; GLYCOPROTEIN GP 120; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; IN VITRO STUDY; NONHUMAN; NORMAL HUMAN; PREDICTION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; VIRUS REPLICATION;

EID: 84874605816     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3016377     Document Type: Article

References (67)

1. Taiwo, B.; Hicks, C.; Eron, J. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1 J. Antimicrob. Chemother. 2010, 65, 1100-1107
2. Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go? J. Med. Chem. 2010, 53, 521-538
3. Dube, M. P.; Sattler, F. R. Inflammation and complications of HIV disease J. Infect. Dis. 2010, 201, 1783-1785
4. Gaardbo, J. C.; Hartling, H. J.; Gerstoft, J.; Nielsen, S. D. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions Clin. Dev. Immunol. 2012, 670957-670974
5. Falutz, J. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 255-260
6. Nuñez, M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity Hepatology 2010, 52, 1143-1155
7. Izzedine, H.; Harris, M.; Perazella, M. A. The nephrotoxic effects of HAART Nat. Rev. Nephrol. 2009, 5, 563-573
8. Yarchoan, R.; Tosato, G.; Little, R. F. Therapy insight: AIDS-related malignancies. The influence of antiviral therapy on pathogenesis and management Nat. Clin. Pract. Oncol. 2005, 2, 406-415 (Pubitemid 43115009)
9. Bhatia, R.; Ryscavage, P.; Taiwo, B. Accelerated aging and human immunodeficiency virus infection: emerging challenges of growing older in the era of successful antiretroviral therapy J. Neurovirol. 2012, 18, 247-255
10. Wainberg, M. A.; Zaharatos, G. J.; Brenner, B. G. Development of antiretroviral drug resistance N. Engl. J. Med. 2011, 365, 637-646
11. Jain, V.; Sucupira, M. C.; Bacchetti, P.; Hartogensis, W.; Diaz, R. S.; Kallas, E. G.; Janini, L. M.; Liegler, T.; Pilcher, C. D.; Grant, R. M.; Cortes, R.; Deeks, S. G.; Hecht, F. M. Differential persistence of transmitted HIV-1 drug resistance mutation classes J. Infect. Dis. 2011, 203, 1174-1181
12. Derdeyn, C. A.; Hunter, E. Entry inhibitors and beyond HIV Chemother. 2005, 195-240
13. Ryser, H.J.-P.; Fluckiger, R. Progress in targeting HIV-1 entry Drug Discovery Today 2005, 10, 1085-1094
14. Castagna, A.; Biswas, P.; Beretta, A.; Lazzarin, A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development Drugs 2005, 65 (7) 879-904 (Pubitemid 40663619)
15. Vermeire, K.; Schols, D. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor Expert Opin. Invest. Drugs 2005, 14 (10) 1199-1212 (Pubitemid 41488869)
16. Rusconi, S.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. An update in the development of HIV entry inhibitors Curr. Top. Med. Chem. 2007, 7 (13) 1273-1289 (Pubitemid 47317047)
17. Veiga, A. S.; Santos, N. C.; Castanho, M. A. R. B. An insight on the leading HIV entry inhibitors Recent Pat. Anti-Infect. Drug Discovery 2006, 1 (1) 67-73
18. Vermeire, K.; Schols, D.; Bell, T. W. Inhibitors of HIV infection via the cellular CD4 receptor Curr. Med. Chem. 2006, 13 (7) 731-743
19. Kadow, J.; Wang, H.-G. H.; Lin, P.-F. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development Curr. Opin. Invest. Drugs 2006, 7 (8) 721-726 (Pubitemid 44263176)
20. Ho, H.-T.; Fan, L.; Nowicka-Sans, B.; McAuliffe, B.; Li, C.-B.; Yamanaka, G.; Zhou, N.; Fang, H.; Dicker, I.; Dalterio, R.; Gong, Y.-F.; Wang, T.; Yin, Z.; Ueda, Y.; Matiskella, J.; Kadow, J.; Clapham, P.; Robinson, J.; Colonno, R.; Lin, P.-F. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events J. Virol. 2006, 80, 4017-40125
21. Yang, Z.; Zadjura, L.; D'Arienzo, C.; Marino, A.; Santone, K.; Klunk, L.; Greene, D.; Lin, P.-F.; Colonno, R.; Wang, T.; Meanwell, N.; Hansel, S. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics Biopharm. Drug Dispos. 2005, 26, 387-402 (Pubitemid 43115915)
22. Lin, P.-F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.-F.; Wang, H.-G. H.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C.-B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11013-11018 (Pubitemid 37140144)
23. Wang, T.; Zhang, Z.; Wallace, O. B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L. M.; Tweedie, D. L.; Huang, S.; Zhao, F.; Ranadive, S.; Robinson, B. S.; Gong, Y.-F.; Ricarrdi, K.; Spicer, T. P.; Deminie, C.; Rose, R.; Wang, H.-G. H.; Blair, W. S.; Shi, P.-Y.; Lin, P.-F.; Colonno, R. J.; Meanwell, N. A. Discovery of 4-benzoyl-1-[(4-methoxy-1 H-pyrrolo[2,3- b ]pyridin-3-yl)oxoacetyl] -2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions J. Med. Chem. 2003, 46, 4236-4239 (Pubitemid 37153004)
24. Wang, J.; Le, N.; Heredia, A.; Song, H.; Redfield, R.; Wang, L.-X. Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120 Org. Biomol. Chem. 2005, 3, 1781-1789
25. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. N -Phenyl- N ′-(2,2,6,6-tetramethyl-piperidin- 4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4 Virology 2005, 339, 213-225 (Pubitemid 41169789)
26. Lu, R.-J.; Tucker, J. A.; Pickens, J.; Ma, Y.-A.; Zinevitch, T.; Kirichenko, O.; Konoplev, V.; Kuznetsova, S.; Sviridov, S.; Brahmachary, E.; Khasanov, A.; Mikel, C.; Yang, Y.; Liu, C.; Wang, J.; Freel, S.; Fisher, S.; Sullivan, A.; Zhou, J.; Stanfield-Oakley, S.; Baker, B.; Sailstad, J.; Greenberg, M.; Bolognesi, D.; Bray, B.; Koszalka, B.; Jeffs, P.; Jeffries, C.; Chucholowski, A.; Sexton, C. Heterobiaryl human immunodeficiency virus entry inhibitors J. Med. Chem. 2009, 52, 4481-4487
27. Tran, T.-D.; Adam, F. M.; Calo, F.; Fenwick, D. R.; Fok-Seang, J.; Gardner, I.; Hay, D. A.; Perros, M.; Rawal, J.; Middleton, D. S.; Parkinson, T.; Pickford, C.; Platts, M.; Randall, A.; Stephenson, P.; Vuong, H.; Williams, D. Design and optimization of potent gp120-CD4 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5250-5255
28. Schoen, A.; Madani, N.; Klein, J. C.; Hubicki, A.; Ng, D.; Yang, X.; Smith, A. B., III; Sodroski, J.; Freire, E. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120 Biochemistry 2006, 45, 10973-10980 (Pubitemid 44360167)
29. Yamada, Y.; Ochiai, C.; Yoshimura, K.; Tanaka, T.; Ohashi, N.; Narumi, T.; Nomura, W.; Harada, S.; Matsushita, S.; Tamamura, H. CD4 mimics targeting the mechanism of HIV entry Bioorg. Med. Chem. Lett. 2010, 20, 354-358
30. Yoshimura, K.; Harada, S.; Shibata, J.; Hatada, M.; Yamada, Y.; Ochiai, C.; Tamamura, H.; Matsushita, S. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds J. Virol. 2010, 84, 7558-7568
31. Hanna, G. J.; Lalezari, J.; Hellinger, J. A.; Wohl, D. A.; Nettles, R.; Persson, A.; Krystal, M.; Lin, P.-F.; Colonno, R.; Grasela, D. M. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects Antimicrob. Agents Chemother. 2011, 55, 722-728
32. Kadow, J. F.; Ueda, Y.; Meanwell, N. A.; Connolly, T. P.; Wang, T.; Chen, C.-P.; Yeung, K.-S.; Zhu, J.; Bender, J. A.; Yang, Z.; Parker, D.; Lin, P.-F.; Colonno, R. J.; Mathew, M.; Morgan, D.; Zheng, M.; Chien, C.; Grasela, D. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1 H -pyrrolo[2,3- c ]pyridin-3-yl)-2-oxoethanone (BMS-488043) J. Med. Chem. 2012, 55, 2048-2056
33. Dahan, A.; Miller, J. M.; Amidon, G. L. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS J. 2009, 11, 740-746
34. Broccatelli, F.; Cruciani, G.; Benet, L. Z.; Oprea, T. I. BDDCS class prediction for new molecular entities Mol. Pharmaceutics 2012, 9 (3) 570-580
35. Meanwell, N. A.; Wallace, O. B.; Fang, H.; Wang, H.; Deshpande, M.; Wang, T.; Yin, Z.; Zhang, Z.; Pearce, B. C.; James, J.; Yeung, K.-S.; Qiu, Z.; Wright, K. J. J.; Yang, Z.; Zadjura, L.; Tweedie, S. Y.; Zhao, F.; Ranadive, S.; Robinson, B. A.; Gong, Y.-F.; Wang, H.-G. H.; Blair, W. S.; Shi, P.-Y.; Colonno, R. J.; Lin, P.-F. Inhibitors of HIV-1 attachment. Part 3: A preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activity Bioorg. Med. Chem. Lett. 2009, 19, 1977-1981
36. Meanwell, N. A.; Wallace, O. B.; Wang, H.; Deshpande, M.; Pearce, B. C.; Trehan, A.; Yeung, K.-S.; Qiu, Z.; Wright, K. J. J.; Robinson, B. A.; Gong, Y.-F.; Wang, H.-G. H.; Blair, W. S.; Shi, P.-Y.; Lin, P.-F. Bioorg. Med. Chem. Lett. 2009, 19, 5136-5139
37. Wang, T.; Kadow, J. F.; Zhang, Z.; Yin, Z.; Gao, Q.; Wu, D.; Parker, D.; Yang, Z.; Zadjura, L.; Robinson, B. A.; Gong, Y.-F.; Blair, W. S.; Shi, P.-Y.; Yamanaka, G.; Meanwell, N. A. Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives Bioorg. Med. Chem. Lett. 2009, 19, 5140-5145
38. Wang, T.; Zhang, Z.; Yang, Z.; Gong, Y.-F.; Riccardi, K. A.; Lin, P.-F.; Parker, D.; Rahematpura, S.; Mathew, M.; Zheng, M.; Meanwell, N. A.; Kadow, J. F.; Bender, J. A. Inhibitors of HIV-1 attachment. Part 10. The discovery and SAR of 4-azaindoles Bioorg. Med. Chem. Lett. 2013, 23, 213-217
39. Bender, J. A.; Yang, Z.; Eggers, B.; Gong, Y.-F.; Lin, P.-F.; Parker, D.; Rahematpura, S.; Zheng, M.; Meanwell, N. A.; Kadow, J. F. Inhibitors of HIV-1 attachment. Part 11. The discovery and structure-activity relationships associated with 4,6-diazaindole cores Bioorg. Med. Chem. Lett. 2013, 239, 218-222
40. Wang, T.; Ueda, Y.; Connolly, T. P.; Chen, C. P.; Yeung, K.-S.; Bender, J.; Yang, Z.; Zhu, J.; Matiskella, J.; Regueiro-Ren, A.; Yin, Z.; Zhang, Z.; Farkas, M.; Yang, X.; Wong, H.; Smith, D.; Raghaven, K. S.; Pendri, Y.; Staab, A.; Soundararajan, N.; Meanwell, N.; Zheng, M.; Parker, D. D.; Adams, S.; Ho, H-T; Yamanaka, G.; Nowicka-Sans, B.; Eggers, B.; McAuliffe, B.; Fang, H.; Fan, L.; Zhou, N.; Gong, Y.-F.; Colonno, R. J.; Lin, P.-F.; Kadow, J. F. Unpublished results.
41. Yeung, K.-S.; Qiu, Z.; Fang, H.; Zheng, Y.; Zadjura, L.; D'Arienzo, C. J.; Eggers, B. J.; Riccardi, K.; Shi, P.-Y.; Gong, Y.-F.; Browning, M. R.; Gao, Q.; Hansel, S.; Santone, K.; Lin, P.-F.; Meanwell, N. A.; Kadow, J. F. Inhibitors of HIV-1 attachment. Part 7: Indole-7-carboxamides as potent and orally bioavailable antiviral agents Bioorg. Med. Chem. Lett. 2013, 23, 198-202
42. Yeung, K.-S.; Qiu, Z.; Yin, Z.; Trehan, A.; Fang, H.; Pearce, B. C.; Yang, Z.; Zadjura, L.; D'Arienzo, C. J.; Riccardi, K.; Shi, P.-Y.; Spicer, T. P.; Gong, Y.-F.; Browning, M. R.; Hansel, S.; Santone, K.; Baker, J.; Coulter, T.; Lin, P.-F.; Meanwell, N. A.; Kadow, J. F. Inhibitors of HIV-1 attachment. Part 8: The effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 203
43. Nesnow, S.; Heidelberger, C. Pyridine nucleosides related to 5-fluorouracil J. Heterocycl. Chem. 1973, 10, 779-784
44. Bartoli, G.; Palmieri, G.; Bosco, M.; Dalpozzo, R. The reaction of vinyl Grignard reagents with 2-substituted nitroarenes: a new approach to the synthesis of 7-substituted indoles Tetrahedron Lett. 1989, 30, 2129-2132 (Pubitemid 19129747)
45. Zhang, Z.; Yang, Z.; Meanwell, N. A.; Kadow, J. F.; Wang, T. A general method for the preparation of 4- and 6-azaindoles J. Org. Chem. 2002, 67, 2345-2347
46. Li, H.; Jiang, X.; Ye, Y.-H.; Fan, C.; Romoff, T.; Goodman, M. 3-(Diethoxyphosphoryloxy)-1,2,3- benzotriazin-4(3 H)-one (DEPBT): a new coupling reagent with remarkable resistance to racemization Org. Lett. 1999, 1, 91-93
47. Surette, J. K. D.; Green, L.; Singer, R. D. 1-Ethyl-3-methylimidazolium haloaluminate melts as reaction media for the Friedel-Crafts acylation of ferrocene Chem. Commun. 1996, 24, 2753-2754 (Pubitemid 127497070)
48. Yeung, K.-S.; Quiu, Z.; Farkas, M. E.; Xue, Q.; Regueiro-Ren, A.; Yang, Z.; Bender, J. A.; Good, A. C.; Kadow, J. F. An efficient one-pot synthesis of 3-glyoxylic acids of electron-deficient substituted azaindoles by ionic liquid imidazolium chloroaluminate-promoted Friedel-Crafts acylation Tetrahedron Lett. 2008, 49, 6250-6253
49. Van Leusen, A. M.; Hoogenboom, B. B.; Siderius, H. Novel and efficient synthesis of oxazoles from tosylmethyl isocyanide and carbonyl compounds Tetrahedron Lett. 1972, 23, 2369-2372
50. Sakamoto, T.; Shiga, F.; Uchiyama, D.; Kondo, Y. I.; Yamanaka, H. Synthesis and reaction of tributylstannylpyrazoles Heterocycles 1992, 33, 813-818
51. Taft, W. R.; Anvia, F.; Taagepera, M.; Catalan, J.; Elguero, J. Electrostatic proximity effects in the relative basicities and acidities of pyrazole, imidazole, pyridazine, and pyrimidine J. Am. Chem. Soc. 1986, 108, 3237-3239
52. Huc, I.; Maurizot, V.; Gornitzka, H.; Leger, J.-M. Hydroxy-substituted oligopyridine dicarboxamide helical foldamers Chem. Commun. 2002, 578-579 (Pubitemid 34259054)
53. The angles were calculated using the following: Jaguar, version 7.8; Schrödinger, LLC: New York, NY, 2011.
54. Chien, R. J.; Corey, E. J. Strong conformational preferences of heteroaromatic ethers and electron pair repulsion Org. Lett. 2010, 12, 132
55. Taylor, R.; Kennard, O. Crystallographic evidence for the existence of CHO, CHN and CHCl hydrogen bonds J. Am. Chem. Soc. 1982, 104, 5063-5070
56. Böhm, H.-J.; Klebe, G.; Brode, U. Oxygen and nitrogen in competitive situations: Which is the hydrogen-bond acceptor? Chem.-Eur. J. 1996, 2, 1509-1513
57. Noveli, I.; Price, S. L.; Lommerse, J. P. M.; Taylor, R. Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles J. Comput. Chem. 1997, 18, 2060-2074 (Pubitemid 127598558)
58. Johnson, V. A.; Byington, R. E. Infectivity Assay (Virus Yield Assay). In Techniques in HIV Research; Aldovini, A.; Walker, B. D., Eds.; Stockton: New York, 1990.
59. Trainor, L. G. The importance of plasma protein binding in drug discovery Expert Opin. Drug Discovery 2007, 1, 51-64
60. Boffito, M.; Back, D. J.; Blaschke, T. F.; Rowland, M.; Bertz, R. J.; Gerber, J. G.; Miller, V. Protein binding in antiretroviral therapies AIDS Res. Hum. Retroviruses 2003, 19, 825-835 (Pubitemid 37215138)
61. Raevsky, O. A.; Schaper, K.-J. Quantitative estimation of hydrogen bond contribution to permeability and absorption processes of some chemicals and drugs Eur. J. Med. Chem. 1998, 33, 799-807 (Pubitemid 29359504)
62. Goodwin, J. T.; Conradi, R. A.; Ho, N. F. H.; Burton, P. S. Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume J. Med. Chem. 2001, 44, 3721-3729 (Pubitemid 33026680)
63. Nettles, R.; Schurmann, D.; Zhu, L.; Stonier, M.; Huang, S.-P.; Chien, C.; Krystal, M.; Wind-Rotolo, M.; Bertz, R.; Grasela, D. Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068: A Potentially First-in-Class Oral HIV Attachment Inhibitor. Presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011; Paper 49.
64. Nettles, R.; Schürmann, D.; Zhu, L.; Stonier, M.; Huang, S.-P.; Chang, I.; Chien, C.; Krystal, M.; Wind-Rotolo, M.; Ray, N.; Hanna, G. J.; Bertz, R.; Grasela, D. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1 infected subjects J. Infect. Dis. 2012, 206, 1002-1011
65. Kadow, J. F.; Ueda, Y.; Connolly, T. P.; Wang, T.; Chen, C. P.; Yeung, K.-S.; Bender, J.; Yang, Z.; Zhu, J.; Matiskella, J.; Regueiro-Ren, A.; Yin, Z.; Zhang, Z.; Farkas, M.; Yang, X.; Wong, H.; Smith, D.; Raghaven, K. S.; Pendri, Y.; Staab, A.; Soundararajan, N.; Meanwell, N.; Zheng, M.; Parker, D. D.; Adams, S.; Ho, H.-T.; Yamanaka, G.; Nowicka-Sans, B.; Eggers, B.; McAuliffe, B.; Fang, H.; Fan, L.; Zhou, N.; Gong, Y.-F.; Colonno, R. J.; Lin, P.-F.; Brown, J.; Grasela, D. M.; Chen, C.; Nettles, R. E. Discovery of BMS-663068, an HIV Attachment Inhibitor for the Treatment of HIV-1. Presented at the 241st National Meeting and Exposition of the American Chemical Society, Anaheim, CA, U.S., March 27-31, 2011; MEDI-29.
66. Nowicka-Sans, B.; Gong, Y.-F.; McAuliffe, B.; Dicker, I.; Ho, H.-T.; Zhou, N.; Eggers, B.; Lin, P.-F.; Ray, N.; Wind-Rotolo, M.; Zhu, L.; Majumdar, A.; Stock, D.; Lataillade, M.; Hanna, G. J.; Matiskella, J. D.; Ueda, Y.; Wang, T.; Kadow, J. F.; Meanwell, M. A.; Krystal, M. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068 Antimicrob. Agents Chemother. 2012, 57, 3498-3507
67. Nowicka-Sans, B.; Gong, Y.-F.; Ho, H.-T.; Colonno, R.; Lin, P.-F.; Wind-Rotolo, M.; Kadow, J.; Meanwell, N.; Nettles, R.; Krystal, M. Antiviral Activity of a New Small Molecule HIV-Attachment Inhibitor, BMS-626529, the Parent of BMS-663068. Presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 27-Mar 2, 2011; Poster 51.